<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166229</url>
  </required_header>
  <id_info>
    <org_study_id>1404013775</org_study_id>
    <nct_id>NCT02166229</nct_id>
  </id_info>
  <brief_title>Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the ability of divalproex sodium, a histone deacetylase inhibitor, to improve&#xD;
      the digital manifestations of scleroderma including digital edema, calcinosis cutis, digital&#xD;
      ulcers, and joint contractures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects were enrolled.&#xD;
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of new digital ulcers</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in modified Rodnan skin score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in digital goniometry measurements</measure>
    <time_frame>12 months</time_frame>
    <description>Goniometry measures range of motion of joints and, in this study, will include measurements of the metacarpophalangeal, proximal interphalangeal, distal interphalangeal and wrist joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hydraulic pinch and hand-grip strength measurements</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in digital circumference</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum oral aperture</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated affected total body surface area</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scleroderma Health Assessment Questionnaire (SHAQ)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new lesions of calcinosis cutis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Scleroderma</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Divalproex sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Divalproex sodium will be initiated at 125 mg twice daily and increased monthly to a maximum dose of 500 mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex sodium</intervention_name>
    <arm_group_label>Divalproex sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Diagnosis of scleroderma as defined by the American College of Rheumatology (ACR)&#xD;
&#xD;
          -  Presence of at least one digital manifestation occurring within the past 6 months,&#xD;
             i.e. digital swelling/edema, digital ulcer, calcinosis cutis, restricted digital range&#xD;
             of motion.&#xD;
&#xD;
          -  Females of childbearing potential must take an oral contraceptive pill or use an&#xD;
             equivalent birth control method during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years old&#xD;
&#xD;
          -  Ongoing use of high dose steroids (&gt;10 mg/day) or unstable steroid dose in past 4&#xD;
             weeks.&#xD;
&#xD;
          -  An investigational drug or disease-modifying agent has been started within the past 6&#xD;
             months, including but not limited to systemic corticosteroids, methotrexate,&#xD;
             cyclosporine, azathioprine, cyclophosphamide, bosentan, mycophenolate mofetil,&#xD;
             thalidomide, colchicine.&#xD;
&#xD;
          -  Patient taking a medication with a significant drug-drug interaction with divalproex&#xD;
             sodium, e.g. clomipramine and lamotrigine.&#xD;
&#xD;
          -  Patient has another connective tissue disease or other condition that could affect&#xD;
             rest pain and hand function, e.g. systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             or osteoarthritis.&#xD;
&#xD;
          -  Patient has uncontrolled diabetes, chronic kidney disease, chronic hepatitis.&#xD;
&#xD;
          -  Any of the following laboratory abnormalities at baseline: anemia (Hb &lt; 8.5 gm/dL),&#xD;
             thrombocytopenia with platelets &lt;100,000, INR &gt; 1.3 or known bleeding disorder,&#xD;
             estimated GFR &lt; 60 mL/min/1.73m2 or serum creatinine &gt; 2.0 mg/dL, hyperbilirubinemia&#xD;
             or elevation of AST or ALT&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  History of severe depression (i.e. depression requiring medical treatment by a&#xD;
             psychiatrist), suicidal ideation, epilepsy, bipolar disorder, or schizophrenia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett King, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

